Asahi Kasei Therapeutics
As of the edition of 20 October 2026, Asahi Kasei Therapeutics runs 12 drugs, 8 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Prednisolone | none listed | 6 |
| Zoledronic acid anhydrous | none listed | 4 |
| Teriparatide | none listed | 3 |
| Collagenase clostridium histolyticum | Ended 1977 (computed from the first US licence) | 0 |
| Famciclovir | none listed | 0 |
| Isavuconazonium | Ends 2031 (exclusivity) | 0 |
| Naftopidil | none listed | 1 |
| Teriparatide acetate | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Asahi Kasei Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 3 trials led
- Skin and connective tissue: 3 trials led
- Bones, joints and muscles: 2 trials led